Charite University – Developmental Therapeutics Review – Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: C2E48999178EN
Leaflet:

Download PDF Leaflet

Summary

Global Market Direct’s pharmaceuticals report, “Charite University – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable). It also gives a complete picture of the institute’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Charite University.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Charite University with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of Charite University’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in Charite University’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Charite University’s position with total access to a detailed intelligence on its therapeutic products development.
- Assess the growth potential of Charite University in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Charite University.
- Avoid Intellectual Property Rights related issues.
- Undertake deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 CHARITE UNIVERSITY - RESEARCH AND DEVELOPMENT OVERVIEW

3.1 Key Therapeutic Areas

4 CHARITE UNIVERSITY - INVESTIGATIONAL PRODUCTS REVIEW

4.1 Products by Stage of Development
4.2 Products - Monotherapy
4.3 Products - Combination Treatment Modalities

5 CHARITE UNIVERSITY - INVESTIGATIONAL PRODUCTS GLANCE

5.1 Charite University - Phase III Products
5.2 Charite University - Phase II Products
5.3 Charite University - Phase I Products
5.4 Charite University - Pre-Clinical and Discovery Products

6 CHARITE UNIVERSITY - DRUG PROFILES

6.1 Product 1 - Product Profile
  6.1.1 Product Description
  6.1.2 Mechanism of Action
  6.1.3 R&D Progress

7 CHARITE UNIVERSITY - INVESTIGATIONAL PRODUCTS ANALYSIS

7.1 Charite University Products by Therapeutic Class
7.2 Charite University Products by Target
7.3 Charite University by Route of Administration
7.4 Charite University Products by Molecule Type

8 CHARITE UNIVERSITY - RECENT PRODUCT UPDATES
9 CHARITE UNIVERSITY - FEATURED NEWS
10 CHARITE UNIVERSITY - LOCATIONS
11 APPENDIX

11.1 Global Markets Direct Research Methodology
11.2 Coverage
11.3 Secondary Research
11.4 Primary Research
11.5 Models
11.6 Expert Panels
11.7 Contact Us
11.8 Disclaimer

LIST OF TABLES

Table 1: Charite University - Key Therapeutic Areas
Table 2: Charite University - Products by Stage of Development,
Table 3: Charite University - Monotherapy Products under Investigation,
Table 4: Charite University - Combination Treatment Modalities under Investigation,
Table 5: Charite University - Phase III Products,
Table 6: Charite University - Phase II Products,
Table 7: Charite University - Phase I Products,
Table 8: Charite University - Pre-Clinical and Discovery Products,
Table 9: Charite University - Products By Therapeutic Class
Table 10: Charite University - Products By Target
Table 11: Charite University - Products By Route of Administration
Table 12: Charite University - Products By Molecule Type
Table 13: Charite University - Recent Product Updates

LIST OF FIGURES

Figure 1: Charite University - Research and Development Overview
Figure 2: Charite University - Products by Stage of Development,
Figure 3: Charite University - Monotherapy Products,
Figure 4: Charite University - Combination Treatment Modalities,
Figure 5: Charite University - Products By Therapeutic Class and Stage of Development
Figure 6: Charite University - Products By Therapeutic Class
Figure 7: Charite University - Products By Target and Stage of Development
Figure 8: Charite University - Products By Target
Figure 9: Charite University - Products By Route of Administration and Stage of Development
Figure 10: Charite University - Products By Route of Administration
Figure 11: Charite University - Products By Molecule Type and Stage of Development
Figure 12: Charite University - Products By Molecule Type

COMPANIES MENTIONED

Charite University

Ask Your Question

Charite University – Developmental Therapeutics Review – Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: